Erythropoietin, but not asialoerythropoietin or carbamyl-erythropoietin, attenuates monocrotaline-induced pulmonary hypertension in rats

Clinical and Experimental Hypertension

Volumn 34, Issue 8, 2012, Pages 575-581

  Ikarashi, Noboru ^a   Toba, Ken ^a   Kato, Kiminori ^a   Ozawa, Takuya ^a   Oda, Masato ^a   Takayama, Tsugumi ^a   Kobayashi, Hironori ^a   Yanagawa, Takao ^a   Hanawa, Haruo ^a   Suzuki, Tomoyasu ^a   Nakazawa, Mikio ^a   Nomoto, Minoru ^a   Asami, Fuyuki ^a   Higuchi, Masato ^b   Saito, Hideki ^b   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Asialoerythropoietin; Carbamyl erythropoietin; Erythropoietin; Monocrotaline; Pulmonary hypertension

Indexed keywords

ASIALOERYTHROPOIETIN; CARBAMYL ERYTHROPOIETIN; CD31 ANTIGEN; CD45 ANTIGEN; ENDOTHELIN 1; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; MONOCROTALINE; PROTEIN BCL 2; PROTEIN BCL XL; SIALIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; BODY WEIGHT; CELL STRESS; CONTROLLED STUDY; ERYTHROID CELL; HEART FUNCTION; HEART RIGHT VENTRICLE PRESSURE; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; IN VIVO STUDY; LUNG ARTERY; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SPLEEN WEIGHT;

ANIMALS; ASIALOGLYCOPROTEINS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RECEPTORS, ERYTHROPOIETIN; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84866950877     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2012.681728     Document Type: Article

References (31)

1. Fishman AP. Changing concepts of the pulmonary plexiform lesion. Physiol Res 2000; 49:485-492.
2. Limsuwan A, Pakakasama S, Hongeng S. Reversible course of pulmonary arterial hypertension related to bone marrow transplantation. Heart Vessels 2011; 26:557-561.
3. Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003; 2:123-137.
4. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105-3111.
5. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157.
6. Chang SA, JangSY,KiCS,Kang IS,KimDK. Successful bosentan therapy for pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia. Heart Vessels 2011; 26:231-234.
7. Newman JH, Fanburg BL, Archer SL, et al. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 2004; 109:2947-2952.
8. Hilliker KS, Bell TG, Roth RA. Pneumotoxicity and thrombocytopenia after single injection of monocrotaline.AmJ Physiol 1982; 242:H573-H577.
9. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293:90-95.
10. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106:2973-2979.
11. Zhande R, Karsan A. Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-kappaBindependent upregulation of Bcl-xL. Am J Physiol Heart Circ Physiol 2007; 292:H2467-H2474.
12. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104:2073-2080.
13. Satoh K, Kagaya Y, Nakano M, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006; 113:1442-1450.
14. vanAlbadaME, duMarchie SarvaasGJ,Koster J,HouwertjesMC, BergerRM,SchoemakerRG. Effects of erythropoietin on advanced pulmonary vascular remodelling. Eur Respir J 2008; 31:126-134.
15. Umar S, Steendijk P, Ypey DL, et al. Novel approaches to treat experimental pulmonary arterial hypertension: a review. J Biomed Biotechnol 2010; 2010:702836.
16. Ozawa T, Toba K, Kato K, et al. Erythroid cells play essential roles in angiogenesis by bone marrow cell implantation. J Mol Cell Cardiol 2006; 40:629-638.
17. Mitsuma W, Ito M, Kodama M, et al. Cardioprotective effects of recombinant human erythropoietin in rats with experimental autoimmune myocarditis. Biochem Biophys Res Commun 2006; 344:987-994.
18. Dong YJ, Kung C, Goldwasser E. Receptor binding of asialoerythropoietin. J Cell Biochem 1992; 48:269-272.
19. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common betasubunit heteroreceptor. Proc Natl Acad Sci USA 2008; 101:14907-14912.
20. Matsuda Y, Hoshikawa Y, Ameshima S, et al. Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi 2005; 43:283-288.
21. Yoshida T, Hanawa H, Toba K, et al. Expression of immunological molecules by cardiomyocytes and inflammatory and interstitial cells in rat autoimmune myocarditis. Cardiovasc Res 2005; 68:278-288.
22. Weigel PH, Yik JH. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim Biophys Acta 2002; 1572:341-363.
23. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76:1718-1722.
24. Nasuno A, Toba K, Ozawa T, et al. Expression of coxsackievirus and adenovirus receptor in neointima of the rat carotid artery. Cardiovasc Pathol 2004; 13:79-84.
25. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361:1533-1544.
26. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005; 96:442-450.
27. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102:1340-1346.
28. Imai N, Higuchi M, Kawamura A, et al. Physicochemical and biological characterization of asialoerythropoietin. Suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro. Eur J Biochem 1990; 194: 457-462.
29. Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003; 100:6741-6746.
30. Yokomaku Y, Sugimoto T, Kume S, et al. Asialoerythropoietin prevents contrast-induced nephropathy. J Am Soc Nephrol 2008; 19:321-328.
31. Lancrin C, Sroczynska P, Serrano AG, et al. Blood cell generation from the hemangioblast. J Mol Med 2010; 88:167-172.